PAP Testing Segment to Dominate North America Cervical Cancer Diagnostic Testing Market During 2021–2028

According to a new market research study on “North America Cervical Cancer Diagnostic Testing Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Type and Service Provider” is expected to reach US$ 3,159.09 million by 2028 from US$ 2,250.53 million in 2021. The market is estimated to grow at a CAGR of 5.0% from 2021 to 2028. The report provides trends prevailing in the North America cervical cancer diagnostic testing market along with the drivers and restraints pertaining to the market growth. Growing prevalence of cervical cancer and rising HPV infections are the major factor driving the growth of the North America cervical cancer diagnostic testing market. However, dearth of awareness about the diagnosis and treatment methods hinders the growth of North America cervical cancer diagnostic testing market.

In case of COVID-19, North America is highly affected the US. The chaotic situation was created in the medical industry across the countries, increased demand for diagnosing and therapeutic devices have dramatically increased in the hospitals. For instance, the demand for ventilators, respirators, and in vitro diagnostic (IVD) tests has risen drastically in hospitals across the countries in the region. The FDA has increased its efforts to support the health of people and has imposed several guidelines and for hospitals and medical device companies. Various companies also enhanced their research and development activities for diagnostics tests and therapeutic devices. Due to the fear of infection of COVID19, women are hesitating to take cervical cancer testing such as the PAP test, biopsies, colonoscopy, and others, as it generally requires an actual visit to the healthcare. This trend among the patients is expected to affect the cervical cancer diagnostic testing market in the region. However, healthcare providers are now offering at-home testing services for the initial diagnosis through point-of-care devices and kits. The market players are actively involved in organic and inorganic developments. Thus, the outbreak of COVID-19 has shown a remarkable impact on market growth in the region. 

The North America cervical cancer diagnostic testing market has been segmented based on type, service provider, and country. Based on type, the market has been segmented into PAP testing, HPV testing, colposcopy, cervical biopsies, cystoscopy, and others. The PAP testing segment dominated the market in 2020 and HPV testing segment is expected to be fastest growing during forecast period. Based on service provider, the market has been segmented into diagnostics and research laboratories, hospitals and clinics, specialty clinics, and home care services. The diagnostics and research laboratories segment dominated the market in 2020 and same segment is expected to be fastest growing during forecast period.  Based on country, the market has been segmented into the US, Canada, and Mexico.

Abbott; BD; Cooper Companies, Inc.; DYSIS Medical Inc; F. Hoffmann-La Roche Ltd.; Femasys Inc.; Guided Therapeutics, Inc; Hologic, Inc.; QIAGEN; and Quest Diagnostics Incorporated are among the leading companies in the North America cervical cancer diagnostic testing market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2021, Hologic Inc launched Genius Digital Diagnostics System for screening cervical cancer in Europe. The next generation screening system combines deep earning-based artificial intelligence (AI) with latest volumetric imaging technology to assist the identification of pre-cancerous lesions and cervical cancer cells in women. 

North America Cervical Cancer Diagnostic Testing Market, By Country, 2020 and 2028 (%)

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com